insitro is a data-driven drug discovery and development company that leverages machine learning and high-throughput biology to transform the way medicines are created to help patients.
insitro is advancing better medicines with predictive models, created by machine learning & biology at scale.
insitro was founded in 2018 by Daphne Koller. The company is headquartered in South San Francisco, California.
insitro is rethinking the entire drug discovery process, from the perspective of machine learning, human genetics, and high-throughput, quantitative biology.
insitro is applying state-of-the-art technologies from bioengineering to create massive data sets that enable the power of modern machine learning methods to be brought to bear on key bottlenecks in pharmaceutical R&D.
insitro is backed by Andreessen Horowitz, Canada Pension Plan Investment Board (CPP Investments), ARCH Venture Partners, Foresite Capital, GV, Third Rock Ventures, Two Sigma Ventures and others. The company raised $143M in an overscribed Series B round on May 26, 2020. This brings insitro's total funding to $243M to date.